FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308402604> ?p ?o ?g. }

• W4308402604 abstract "<h3>Background</h3> T-cell engaging bispecific antibody molecules (BsAb) redirect T cells towards antigen-expressing cells and have shown efficacy in various B-cell malignancies.^1-3 The CD19xCD3 BsAb blinatumomab was the first in class to be approved in the setting of R/R BCP-ALL with a response rate of 43%.⁴ Evaluating mechanisms of resistance to bispecifics has been hampered by a lack of an appropriate model to mimic the clinical application of continuous BsAb exposure over several weeks to months. We developed an <i>in vitro</i> model system to simulate the clinical administration of blinatumomab as continuous infusion over 28 days and demonstrated that continuous exposure to a BsAb induces T-cell exhaustion.⁵ To identify partners for bispecifics to mitigate exhaustion, a diverse toolbox of off-the-shelf immunomodulating agents was evaluated. Using our <i>in vitro</i> model system, we explored the potential of BsAb treatment in combination with i) the tyrosine kinase inhibitor dasatinib, ii) the immunomodulator lenalidomide and iii) aPD-1/aPD-L1 checkpoint blockade to enhance T-cell function (figure 1). <h3>Methods</h3> Healthy donor T cells were cocultured with CD19⁺ OCI-Ly1 cells and continuously stimulated with a CD19xCD3 BsAb alone or in combination with dasatinib (12.5 nM), lenalidomide (10 µg/ml), nivolumab (10 µg/ml) or atezolizumab (10 µg/ml) for 28 days. Every 7 days, T cells were isolated and characterized in functional assays: (1) Expression of inhibitory receptors (IRs; PD-1, Tim-3, LAG-3), (2) BsAb-mediated cytotoxicity against hCD19-Ba/F3 cells after 72h, (3) T-cell expansion as fold change of CD2⁺ counts, (4) BsAb-mediated cytokine secretion measured via intracellular staining or in supernatants. <h3>Results</h3> Dasatinib reduced IR co-expression and led to an increased proliferative and cytotoxic potential of T cells after 14 days of BsAb stimulation. Furthermore, it strongly increased granzyme B expression and secretion of IL-2 and IFN-g. Lenalidomide did not affect IR co-expression, but increased cytotoxicity of T cells after 14 and 21 days of BsAb stimulation. Additionally, it increased IL-2 and IFN-g secretion. Interestingly, both nivolumab and atezolizumab did not enhance T-cell function, suggesting a minor role of the PD-1/PD-L1 axis in the induction of exhaustion in our model system. <h3>Conclusions</h3> Together, our findings highlight that T-cell function during BsAb stimulation <i>in vitro</i> strongly improves by combinatorial treatment with dasatinib or lenalidomide. Albeit checkpoint inhibitors can boost T-cell responses, they could not ameliorate BsAb-induced T-cell exhaustion. Our data supports combinatorial approaches of BsAbs and small molecules to achieve durable T-cell responses in patients. <h3>References</h3> Kantarjian H, Stein A, Gokbuget N, <i>et al</i>. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. <i>The New England Journal of Medicine</i>. 2017;<b>376</b>(9):836–847. Goldstein RL, Goyos A, Li CM, <i>et al</i>. AMG 701 induces cytotoxicity of multiple myeloma cells and depletes plasma cells in cynomolgus monkeys. <i>Blood Adv</i>. 2020;<b>4</b>(17):4180–4194. Hutchings M, Morschhauser F, Iacoboni G, <i>et al</i>. Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial. <i>Journal of Clinical Oncology : Official Journal of The American Society of Clinical Oncology</i>. 2021;39(18):1959–1970. Zugmaier G, Gokbuget N, Klinger M, <i>et al</i>. Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment. <i>Blood</i>. 2015;<b>126</b>(24):2578–2584. Philipp N, Kazerani M, Nicholls A, <i>et al</i>. T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals. <i>Blood</i>.2022;online ahead of print <h3>Ethics Approval</h3> Peripheral blood (PB) were collected from healthy donors (HDs) after written informed consent was received in accordance with the Declaration of Helsinki and approval was granted by the Institutional Review Board of the Ludwig-Maximilian-Universitaet (Munich, Germany; ID 216-08)." @default.
• W4308402604 created "2022-11-11" @default.
• W4308402604 creator A5003069482 @default.
• W4308402604 creator A5017861385 @default.
• W4308402604 creator A5034688689 @default.
• W4308402604 creator A5083259904 @default.
• W4308402604 creator A5086730170 @default.
• W4308402604 date "2022-11-01" @default.
• W4308402604 modified "2023-09-25" @default.
• W4308402604 title "897 Partners for bispecifics: combinatorial approaches to augment T-cell function and mitigate exhaustion" @default.
• W4308402604 doi "https://doi.org/10.1136/jitc-2022-sitc2022.0897" @default.
• W4308402604 hasPublicationYear "2022" @default.
• W4308402604 type Work @default.
• W4308402604 citedByCount "0" @default.
• W4308402604 crossrefType "proceedings-article" @default.
• W4308402604 hasAuthorship W4308402604A5003069482 @default.
• W4308402604 hasAuthorship W4308402604A5017861385 @default.
• W4308402604 hasAuthorship W4308402604A5034688689 @default.
• W4308402604 hasAuthorship W4308402604A5083259904 @default.
• W4308402604 hasAuthorship W4308402604A5086730170 @default.
• W4308402604 hasBestOaLocation W43084026041 @default.
• W4308402604 hasConcept C126322002 @default.
• W4308402604 hasConcept C147483822 @default.
• W4308402604 hasConcept C170493617 @default.
• W4308402604 hasConcept C185592680 @default.
• W4308402604 hasConcept C203014093 @default.
• W4308402604 hasConcept C2776090121 @default.
• W4308402604 hasConcept C2777701055 @default.
• W4308402604 hasConcept C2778020697 @default.
• W4308402604 hasConcept C2778957590 @default.
• W4308402604 hasConcept C2779536868 @default.
• W4308402604 hasConcept C2780030458 @default.
• W4308402604 hasConcept C42362537 @default.
• W4308402604 hasConcept C502942594 @default.
• W4308402604 hasConcept C71924100 @default.
• W4308402604 hasConcept C8891405 @default.
• W4308402604 hasConcept C98274493 @default.
• W4308402604 hasConceptScore W4308402604C126322002 @default.
• W4308402604 hasConceptScore W4308402604C147483822 @default.
• W4308402604 hasConceptScore W4308402604C170493617 @default.
• W4308402604 hasConceptScore W4308402604C185592680 @default.
• W4308402604 hasConceptScore W4308402604C203014093 @default.
• W4308402604 hasConceptScore W4308402604C2776090121 @default.
• W4308402604 hasConceptScore W4308402604C2777701055 @default.
• W4308402604 hasConceptScore W4308402604C2778020697 @default.
• W4308402604 hasConceptScore W4308402604C2778957590 @default.
• W4308402604 hasConceptScore W4308402604C2779536868 @default.
• W4308402604 hasConceptScore W4308402604C2780030458 @default.
• W4308402604 hasConceptScore W4308402604C42362537 @default.
• W4308402604 hasConceptScore W4308402604C502942594 @default.
• W4308402604 hasConceptScore W4308402604C71924100 @default.
• W4308402604 hasConceptScore W4308402604C8891405 @default.
• W4308402604 hasConceptScore W4308402604C98274493 @default.
• W4308402604 hasLocation W43084026041 @default.
• W4308402604 hasOpenAccess W4308402604 @default.
• W4308402604 hasPrimaryLocation W43084026041 @default.
• W4308402604 hasRelatedWork W1635229836 @default.
• W4308402604 hasRelatedWork W2559935001 @default.
• W4308402604 hasRelatedWork W2913949832 @default.
• W4308402604 hasRelatedWork W2953853904 @default.
• W4308402604 hasRelatedWork W2992270245 @default.
• W4308402604 hasRelatedWork W2997778794 @default.
• W4308402604 hasRelatedWork W3110391218 @default.
• W4308402604 hasRelatedWork W3145562791 @default.
• W4308402604 hasRelatedWork W4308402604 @default.
• W4308402604 hasRelatedWork W4361824780 @default.
• W4308402604 isParatext "false" @default.
• W4308402604 isRetracted "false" @default.
• W4308402604 workType "article" @default.